Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORATRAM: Combined CRAF and MEK inhibition in BRAF-impaired advanced malignancies
2024-512887-77-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and trametinib in cancer, sponsored by Universitätsklinikum Freiburg. Primary endpoint: Maximum tolerated dose of trametinib in combination with sorafenib. Planned start Oct 2024; status: authorised.
02
Drugs
sorafenibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-512887-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512887-77-00.